Abogen Biosciences 2024 Year-End Review: Innovation, Pipeline Progress, and IPO Filing

Related Reading

Abogen Biosciences' mRNA Vaccine for COVID-19 Variant Completes Phase III Clinical Study Results Published

Breaking Through Overseas Patent Barriers, Abogen Successfully Develops Circular RNA Based on the Cis System

【First Case of Complete Tumor Remission · New Breakthrough in Lung Cancer Treatment】Clinical Progress of the World's First mRNA Tumor Vaccine Targeting EGFR Mutations

【Post-Conference Report】The 8th China Nucleic Acid Vaccine Conference Concludes Successfully

Abogen and Ruijin Hospital Jointly Establish Research Institute to Accelerate Clinical Translation of mRNA Drugs

Abogen Biosciences Honored on the "2024 Hurun China New Medical Powerhouse Enterprises" List

About Us

Abogen Biosciences Co., Ltd. (Abbr. "Abogen") is an innovative biopharmaceutical company focused on the research and development of messenger ribonucleic acid (mRNA) drugs. The company owns industry-leading, proprietary technology platforms in mRNA and nanodelivery, and is one of the few mRNA drug research and development enterprises in China with complete value chain capabilities, covering all aspects from mRNA design, formulation development to large-scale production. The company has established a rich product pipeline, spanning multiple fields including infectious disease prevention and control, cancer immunotherapy, protein replacement therapy, and more, with its mRNA COVID-19 vaccine as one of the key products.